Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Soleno Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company ...

Over the last week, the United States market saw a 3.1% increase, contributing to a 24% climb over the past year, with earnings forecasted to grow by 15% annually. In this environment of robust growth ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have received a consensus recommendation of “Buy” from the seven research firms that are covering the company, MarketBeat.com ...

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are ...

REDWOOD CITY, CA—Soleno Therapeutics Inc. (NASDAQ:SLNO), a $1.98 billion market cap biopharmaceutical company, recently disclosed a series of stock sales by Kristen Yen, the company's Senior Vice ...

Patricia Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc. (NASDAQ:SLNO), recently sold shares of the company. According to a filing with the Securities and Exchange ...

Anish Bhatnagar, the Chief Executive Officer of Soleno Therapeutics Inc. (NASDAQ:SLNO), recently sold a significant portion of the company's stock. According to an SEC filing, Bhatnagar sold a total ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan. Check the time stamp on this data. Updated AI-Generated Signals for Soleno Therapeutics ...